2.2200
08-January-25 15:45:00
15 minutes delayed
Stocks
-0.0400
-1.77%
Today's range
2.1600 - 2.3392
ISIN
N/A
Source
NASDAQ
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
18 Apr 2024 06:00:00 By Nasdaq GlobeNewswire
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 Apr 2024 06:00:00 By Nasdaq GlobeNewswire
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 Mar 2024 06:06:46 By Nasdaq GlobeNewswire